Research programme: diagnostic imaging - Mallinckrodt

Drug Profile

Research programme: diagnostic imaging - Mallinckrodt

Alternative Names: Diagnostic imaging research programme - Mallinckrodt

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Mallinckrodt Inc.; Mallinckrodt Medical
  • Developer Mallinckrodt Inc.
  • Class Peptide diagnostics
  • Mechanism of Action Neurotensin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA
  • 13 Aug 2003 Preclinical trials in Diagnostic imaging in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top